Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

New data from Novo Nordisk’s phase 3 trial ... The 50 mg oral semaglutide pill achieved a 15.1% weight loss in the phase 3 OASIS study involving patients who were overweight or obese, but ...

Demand for GLP-1-based medications ... I took a deeper look at some of Novo Nordisk’s most promising pipeline treatments for diabetes, like IcoSema or oral semaglutide. Obesity treatments ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

If you invested in Novo Nordisk, you are encouraged ... 2.4 mg cagrilintide and 2.4 mg semaglutide for the remainder of the trial period. In truth, REDEFINE-1 employed a flexible dosing design ...

If you invested in Novo Nordisk, you are encouraged ... 2.4 mg cagrilintide and 2.4 mg semaglutide for the remainder of the trial period. In truth, REDEFINE-1 employed a flexible dosing design ...

But the company that makes those drugs, Novo Nordisk, has the exclusive right to make those injector pens. So compounded semaglutide is sold in a vial ... A poll last year estimated that as many as 1 ...

Although the ad does not identify the medication, Hims & Hers offers compounded versions of the weight-loss drug semaglutide, which was developed by Novo Nordisk ... said the 1-minute ad is ...